Review in Natural product reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed.
AssessingJournal of fungi (Basel, Switzerland) · 2026
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Benjamin PhilmusDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, OR, 97333, USA. benjamin.philmus@oregonstate.edu.ORCID 0000-0003-2085-0873
Nicole E AvalonDepartment of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, 92617, USA.ORCID 0000-0003-3588-892X
Yousong DingDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0001-8610-0659
Drew T DoeringU.S. Department of Energy, Joint Genome Institute, Lawrence Berkeley National Laboratory, One Cyclotron Road, Berkeley, CA 94720, USA.ORCID 0000-0003-1884-9902
Alessandra S EustáquioDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois, Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-7852-7844
William H GerwickCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92092, USA.ORCID 0000-0003-1403-4458
Hendrik LueschDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0002-4091-7492
Jimmy OrjalaDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois, Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-4420-2048
Shaz SutherlandDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, OR, 97333, USA. benjamin.philmus@oregonstate.edu.ORCID 0009-0002-3434-025X
Arnaud TatonSchool of Biological Sciences, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-5494-5964
Daniel UdwaryU.S. Department of Energy, Joint Genome Institute, Lawrence Berkeley National Laboratory, One Cyclotron Road, Berkeley, CA 94720, USA.ORCID 0000-0002-3491-0198
Funding
Project 3:Isolation Chemistry of Filamentous Fungi and Biological EvaluationP01CA125066 · NCI · OHIO STATE UNIVERSITY · PI JIMMY ORJALA · 2007 to 2026
$27.2M
Integrative Multidisciplinary Discovery Platform to Unlock Marine Natural Products Therapeutic OpportunitiesRM1GM145426 · NIGMS · UNIVERSITY OF FLORIDA · PI Mohamed Abou Donia, Steven D Bruner · 2022 to 2026
$8.8M
Unified Computation Tools for Natural Products ResearchR01GM107550 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COTTRELL, GARRISON W, GERWICK, WILLIAM HENRY · 2013 to 2025
$8.2M
Undergraduate Summer Research Experience: Molecular and cellular mechanisms of circadian timekeeping in a prokaryote modelR35GM118290 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GOLDEN, SUSAN S · 2016 to 2025
$6.7M
NIH Equipment Supplement to R35GM128742R35GM128742 · NIGMS · UNIVERSITY OF FLORIDA · PI Yousong Ding · 2018 to 2026
$3.4M
Research Training in Natural Product Complementary and Integrative Health - Diversity Supplement to T32 Predoctoral Training GrantT32AT010131 · NCCIH · OREGON STATE UNIVERSITY · PI TAIFO MAHMUD, RICHARD B VAN BREEMEN · 2020 to 2026
$1.8M
A workflow for identification of gene clusters and heterologous expression of cyanobacterial natural productsR15GM117541 · NIGMS · OREGON STATE UNIVERSITY · PI PHILMUS, BENJAMIN · 2016 to 2016
Cyanobacteria are prolific producers of biologically active compounds that are important in influencing ecology, behavior of interacting organisms, and as leads in drug discovery efforts. Here we discuss the challenges faced by all natural product researchers, especially those that focus on cyanobacteria, and then describe progress that has been made in these areas. We also propose some solutions, paths forward, and thoughts for consideration on these challenges.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Green genes from blue greens: challenges and solutions to unlocking the potential of cyanobacteria in drug discovery. · full record | OpenQuestion